Clinical trial

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

NCT06411210

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-07-16

PhasePHASE2

Study timeline

Study start (actual)2024-07-16Date precision: day

Registry last updated2026-08-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes type1unresolved

Obesityunresolved

Interventions

Semaglutide Pen InjectorDRUG · verified · RxNorm: semaglutide Pen Injector

PlaceboDRUG

Sponsors & collaborators

Yale Universitylead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

Novo Nordisk A/Scollaborator

Mapped research locations

New HavenConnecticut, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06411210 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.